While the reduction in price target could suggest a slightly less optimistic outlook on the stock's valuation, the maintenance of a Buy rating indicates that Citigroup still sees positive potential in Apellis Pharmaceuticals. The impact on the stock price is likely to be neutral in the short term as the positive recommendation is counterbalanced by a lower price target.